Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

AHK-Cu Alternative to Finasteride: Comparison Table

The following table compares finasteride and AHK-Cu across mechanism, clinical evidence, dosing, side effect profile, and suitability for different patient priorities. Primary Mechanism Competitive inhibition of type II 5-alpha reductase. Reduces serum DHT by

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • The following table compares finasteride and AHK-Cu across mechanism, clinical evidence, dosing, side effect profile, and suitability for different patient priorities.
  • Primary Mechanism
  • Competitive inhibition of type II 5-alpha reductase. Reduces serum DHT by ~70% systemically
  • Androgen receptor modulation and anti-inflammatory signaling at follicle level. Does not alter systemic DHT
  • Finasteride targets hormone production; AHK-Cu targets cellular response to hormone
  • Clinical Evidence
  • Phase III RCTs with 1,553 participants over 5 years. 83% maintained hair at 2 years, 48% showed regrowth at 5 years
  • In vitro studies and small observational cohorts. No large-scale placebo-controlled human trials
  • Finasteride has definitive efficacy data; AHK-Cu remains investigational
  • Onset of Effect
  • Stabilization visible at 6 months; regrowth peaks at 12–24 months if it occurs
  • Observational data suggests visible changes at 16–24 weeks in responsive users
  • Both are slow-acting; neither produces rapid cosmetic improvement
  • Sexual Side Effects
  • 3.8–15.8% experience reduced libido, erectile dysfunction, or ejaculatory changes
  • None reported. Peptide does not cross blood-brain barrier or suppress neurosteroids
  • AHK-Cu avoids the primary concern driving alternative treatment interest
  • Systemic Hormonal Impact
  • Serum DHT reduced 64–70%; slight increase in testosterone (~9%); neurosteroid suppression documented
  • No measurable impact on serum androgens or neurosteroid levels
  • Critical differentiator for men concerned about hormonal disruption
  • Suitability
  • Men seeking clinically proven efficacy willing to accept hormonal trade-offs
  • Men prioritizing systemic safety over established clinical evidence, or as adjunct to minoxidil
  • Finasteride for proven efficacy; AHK-Cu for risk-averse experimentation

Related resources

More comparisons